Scholarlink

Objective <p>To investigate intra-host evolution of SARS-CoV-2 in critically ill patients with severe lung failure.</p> Methods <p>Between November 2020 to December 2022, respiratory samples were collected from 41 mechanically ventilated patients at the intensive care unit of University Hospital Regensburg, Germany, including 16 on extracorporeal membrane oxygenation (ECMO). Paired initial and follow-up samples were obtained at a median interval of 15 days (range: 6–42) and analyzed using next-generation sequencing. Amino acid substitutions in the viral genome were correlated with clinical, virological, immunological, and therapeutic markers using binary logistic regression.</p> Results <p>Seventeen of 41 patients (41%) developed amino acid substitutions in non-structural proteins (nsp2, 3, 4, 10, 12, 14, and 15), ORF3a, ORF8, and structural proteins (spike and nucleocapsid). Among 27 identified mutations, 21 were single nucleotide polymorphisms, and 6 were nucleotide deletions (3 single, 3 multiple). Notably, 20 mutations (74.1%) represented reversions to the ancestral Wuhan-1 sequence, including eight at position 323 in nsp12. Mutation occurrence was significantly associated with younger age, prolonged ICU stay, ECMO therapy, catecholamine use, thrombotic events, extended viral replication, and Delta variant infection (<i>p</i> &lt; 0.05), whereas Remdesivir therapy showed a negative association. Multivariate analysis confirmed younger age, prolonged replication, and ECMO as independent predictors of intra-host viral evolution.</p> Conclusions <p>Intra-host SARS-CoV-2 evolution in critically ill patients is driven by disease severity and prolonged viral replication. Frequent reversions to the ancestral sequence suggest selective pressure favoring wildtype variants in inflamed and hypoxic lung areas – a process attenuated by the administration of Remdesivir.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Back to the wildtype: SARS-CoV-2 evolution in critically ill patients with severe lung failure

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月8日

查看全文
  • Tanja Kraft,
  • Clara L. Magnus,
  • Andreas Hiergeist,
  • Jürgen J. Wenzel,
  • Philipp Schuster,
  • Matthias Vogel,
  • Frank Hanses,
  • Thomas Dienemann,
  • Roland Schneckenpointner,
  • Matthias Lubnow,
  • Thomas Müller,
  • Dirk Lunz,
  • Florian Hitzenbichler,
  • Stephan Schmid,
  • Martina Müller,
  • Viola Haehnel,
  • Andreas-Michael Brosig,
  • Robert Offner,
  • Hendrik Poeck,
  • Bernhard Graf,
  • André Gessner,
  • Bernd Salzberger,
  • Clemens Wiest,
  • Barbara Schmidt

摘要

Objective

To investigate intra-host evolution of SARS-CoV-2 in critically ill patients with severe lung failure.

Methods

Between November 2020 to December 2022, respiratory samples were collected from 41 mechanically ventilated patients at the intensive care unit of University Hospital Regensburg, Germany, including 16 on extracorporeal membrane oxygenation (ECMO). Paired initial and follow-up samples were obtained at a median interval of 15 days (range: 6–42) and analyzed using next-generation sequencing. Amino acid substitutions in the viral genome were correlated with clinical, virological, immunological, and therapeutic markers using binary logistic regression.

Results

Seventeen of 41 patients (41%) developed amino acid substitutions in non-structural proteins (nsp2, 3, 4, 10, 12, 14, and 15), ORF3a, ORF8, and structural proteins (spike and nucleocapsid). Among 27 identified mutations, 21 were single nucleotide polymorphisms, and 6 were nucleotide deletions (3 single, 3 multiple). Notably, 20 mutations (74.1%) represented reversions to the ancestral Wuhan-1 sequence, including eight at position 323 in nsp12. Mutation occurrence was significantly associated with younger age, prolonged ICU stay, ECMO therapy, catecholamine use, thrombotic events, extended viral replication, and Delta variant infection (p < 0.05), whereas Remdesivir therapy showed a negative association. Multivariate analysis confirmed younger age, prolonged replication, and ECMO as independent predictors of intra-host viral evolution.

Conclusions

Intra-host SARS-CoV-2 evolution in critically ill patients is driven by disease severity and prolonged viral replication. Frequent reversions to the ancestral sequence suggest selective pressure favoring wildtype variants in inflamed and hypoxic lung areas – a process attenuated by the administration of Remdesivir.